The Impact of the Pharma Directive on the European Life Science Industry

The European Commission pharmaceutical package includes a new directive and regulation for basic pharmaceutical legislation (Directive 2001/83/EC and Regulation (EC) No 726/2004). The goal is to improve access to medicines, foster innovation, streamline supply, adapt to new developments, and reduce regulatory burdens where possible.

In the European Parliament, the ENVI Committee approved some amendments to both the Directive and the Regulation in March, and the plenary approved both in April, just one week before this event.

Join us in Brussels to discuss how this revision can enhance the competitiveness and appeal of the EU pharmaceutical industry.

Event Details

Date: Tuesday, 16th April 2024 

• Location: 227 rue de la Loi / Wetstraat, 1040 Brussels 
• Time: 12:00 PM to 1:30 PM

Agenda

• 12:00 PM - Welcome & Opening Address by Ana Coelho, Director of ACCIÓ-Catalonia Trade & Investment office in Brussels.
• 12:15 PM - Panel discussion on "The Impact of the Pharma Directive on the European Life Science Industry", featuring:
  • MEP Pernille Weiss, Rapporteur for the new Directive at the ENV Committee of the European Parliament
  • Ava Lloyd, Director of Government Affairs & Policy, Europe & Canada / Head of EU Office, AstraZeneca ​​​​​​​
  • Elisa Díaz, Associate Director Europe Government & Public Affairs at Merck Group
  • The discussion will be moderated by Roberta Savli, Executive Director of Public Affairs, EFPIA (European Federation of Pharmaceutical Industries and Associations)
• 1:00 PM - Audience Q&A
• 1:15 PM - Conclusions by Jordi Just, Foreign Investment Manager, ACCIÓ-Catalonia Trade & Investment office in Brussels.
• 1:30 PM - Networking Opportunity with a glass of Cava

Registration

The event is free but has limited seats. Register at: https://forms.office.com/e/hAWXMzSp07​​​​​​​